Clinical Challenges: Test Your Knowledge on NASH/MASH
A recent MedPage Today “Clinical Challenges” series on metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis, or NASH) tackled the need to raise patient/physician awareness of the increasing prevalence of the liver disease, lifestyle approaches to managing affected patients of all ages, and promising treatments in the pipeline. The following is a three-question quiz to test […]
‘Game Changer’ in NASH: Resmetirom Hits Endpoints in Pivotal Study
VIENNA — The investigational agent resmetirom resolved liver biopsy findings in nonalcoholic steatohepatitis (NASH) more often than placebo, according to the phase III MAESTRO-NASH trial. While 10% of placebo patients achieved resolution of inflammation, ballooning, and disease activity, the rate was 26% among people treated with the 80-mg dose of resmetirom and 30% with the […]